Cargando…

Topical Selenium Sulfide for the Treatment of Hyperkeratosis

Hyperkeratosis presents as thickened skin. It can be congenital or acquired. Typically, it affects the palms and soles; the distribution of epidermal involvement is either diffuse, focal, or punctate. Microscopically, the pathologic signature of hyperkeratosis is marked orthokeratosis of the stratum...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Philip R., Anderson, Caesar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261123/
https://www.ncbi.nlm.nih.gov/pubmed/30203232
http://dx.doi.org/10.1007/s13555-018-0259-9
_version_ 1783374925978927104
author Cohen, Philip R.
Anderson, Caesar A.
author_facet Cohen, Philip R.
Anderson, Caesar A.
author_sort Cohen, Philip R.
collection PubMed
description Hyperkeratosis presents as thickened skin. It can be congenital or acquired. Typically, it affects the palms and soles; the distribution of epidermal involvement is either diffuse, focal, or punctate. Microscopically, the pathologic signature of hyperkeratosis is marked orthokeratosis of the stratum corneum. Topical treatments provide the mainstay of therapy for hyperkeratosis. These include keratolytics (such as urea, salicylic acid, and lactic acid) and retinoids; physical debridement, topical corticosteroids, and phototherapy (using topical psoralen and ultraviolet A phototherapy) are other local therapeutic modalities. Selenium is a non-metallic essential element; its water-insoluble salt, selenium sulfide, is an active ingredient that is used (in either a foam, lotion, or shampoo) to treat not only seborrheic dermatitis but also tinea versicolor. Three individuals with hyperkeratosis involving their palms and/or soles are described; the hyperkeratosis was successful treated with topical selenium sulfide in either a 2.5% lotion/shampoo or a 2.75% foam. The response to topical selenium sulfide was not only rapid but also complete and sustained; none of the patients experienced any adverse events secondary to the therapy. In conclusion, we recommend that topical selenium sulfide be added to the therapeutic armamentarium for congenital or acquired hyperkeratosis—particularly for those patients with involvement of their palms and soles.
format Online
Article
Text
id pubmed-6261123
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-62611232018-12-11 Topical Selenium Sulfide for the Treatment of Hyperkeratosis Cohen, Philip R. Anderson, Caesar A. Dermatol Ther (Heidelb) Case Report Hyperkeratosis presents as thickened skin. It can be congenital or acquired. Typically, it affects the palms and soles; the distribution of epidermal involvement is either diffuse, focal, or punctate. Microscopically, the pathologic signature of hyperkeratosis is marked orthokeratosis of the stratum corneum. Topical treatments provide the mainstay of therapy for hyperkeratosis. These include keratolytics (such as urea, salicylic acid, and lactic acid) and retinoids; physical debridement, topical corticosteroids, and phototherapy (using topical psoralen and ultraviolet A phototherapy) are other local therapeutic modalities. Selenium is a non-metallic essential element; its water-insoluble salt, selenium sulfide, is an active ingredient that is used (in either a foam, lotion, or shampoo) to treat not only seborrheic dermatitis but also tinea versicolor. Three individuals with hyperkeratosis involving their palms and/or soles are described; the hyperkeratosis was successful treated with topical selenium sulfide in either a 2.5% lotion/shampoo or a 2.75% foam. The response to topical selenium sulfide was not only rapid but also complete and sustained; none of the patients experienced any adverse events secondary to the therapy. In conclusion, we recommend that topical selenium sulfide be added to the therapeutic armamentarium for congenital or acquired hyperkeratosis—particularly for those patients with involvement of their palms and soles. Springer Healthcare 2018-09-10 /pmc/articles/PMC6261123/ /pubmed/30203232 http://dx.doi.org/10.1007/s13555-018-0259-9 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Cohen, Philip R.
Anderson, Caesar A.
Topical Selenium Sulfide for the Treatment of Hyperkeratosis
title Topical Selenium Sulfide for the Treatment of Hyperkeratosis
title_full Topical Selenium Sulfide for the Treatment of Hyperkeratosis
title_fullStr Topical Selenium Sulfide for the Treatment of Hyperkeratosis
title_full_unstemmed Topical Selenium Sulfide for the Treatment of Hyperkeratosis
title_short Topical Selenium Sulfide for the Treatment of Hyperkeratosis
title_sort topical selenium sulfide for the treatment of hyperkeratosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261123/
https://www.ncbi.nlm.nih.gov/pubmed/30203232
http://dx.doi.org/10.1007/s13555-018-0259-9
work_keys_str_mv AT cohenphilipr topicalseleniumsulfideforthetreatmentofhyperkeratosis
AT andersoncaesara topicalseleniumsulfideforthetreatmentofhyperkeratosis